LIFES AND LIMBS: ACCESS TO SECONDARY PREVENTION WITH AAS AND RIVAROXABAN IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE
DOI:
https://doi.org/10.48750/acv.381Keywords:
Peripheral arterial disease, Secondary prevention, Antiplatelet, Anticoagulation, Adverse eventsAbstract
.
Downloads
Download data is not yet available.
References
1. Song P, Rudan D, Zhu Y, Fowkes F, Rajimi K, Fowkes G. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet. 2019 Nov;7(8):E1020-E1030
2. Ambler GK, Wladron C-A, Contractor UB, Hinchliffe RJ, Twine CP. Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br J Surg. 2020 Jan;107(1):20-32
3. Aboyans V, Ricco JB, Bartelink MEL et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2018;39:763–816.
4. Anand SS, Bosch J, Eikelboom JW et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219–229.
5. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004.
6. Hess CN, Wang TY, Fu JW, et al. Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. J Am Coll Cardiol. 2020 Feb 11;75(5):498-508
2. Ambler GK, Wladron C-A, Contractor UB, Hinchliffe RJ, Twine CP. Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br J Surg. 2020 Jan;107(1):20-32
3. Aboyans V, Ricco JB, Bartelink MEL et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J 2018;39:763–816.
4. Anand SS, Bosch J, Eikelboom JW et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet 2018;391:219–229.
5. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004.
6. Hess CN, Wang TY, Fu JW, et al. Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. J Am Coll Cardiol. 2020 Feb 11;75(5):498-508
Downloads
Published
2021-03-05
How to Cite
1.
Bastos Goncalves F, Valentim HD. LIFES AND LIMBS: ACCESS TO SECONDARY PREVENTION WITH AAS AND RIVAROXABAN IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE. Angiol Cir Vasc [Internet]. 2021 Mar. 5 [cited 2024 Apr. 25];16(4):197-9. Available from: https://acvjournal.com/index.php/acv/article/view/381
Issue
Section
Letter
